Barclays raised the firm’s price target on Merck to $145 from $135 and keeps an Overweight rating on the shares. The company reported a “compelling” 2024 guide, incremental positive commentary on launches and drivers, and a handful of upside nuggets that more than overshadow an “uneven” Q4 print, the analyst tells investors in a research note. The firm says Merck remains the easiest story to own in pharma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Merck & Company Launches 2024 Global Restructuring Program
- Merck (NYSE:MRK) Delivers Better-than-Expected Results in Q4
- Options Volatility and Implied Earnings Moves Today, February 01, 2024
- Notable companies reporting before tomorrow’s open
- Senate Health, Education, Labor & Pensions Committee holds an executive session
